SOURCE: Eurand N.V.

Eurand N.V.

September 16, 2009 08:43 ET

Eurand to Present at UBS Global Life Sciences Conference

PHILADELPHIA, PA--(Marketwire - September 16, 2009) - Eurand N.V. (NASDAQ: EURX), a specialty pharmaceutical company that develops enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies, announced today that John Fraher, Chief Commercial Officer, is scheduled to present at the following conference:

Event:      UBS Global Life Sciences Conference
Date:       Monday, September 21, 2009
Time:       1:30 p.m. ET
Location:   Grand Hyatt Hotel
            New York, N.Y.

An audio webcast of the Company's presentation will be available by accessing the investor relations section of Eurand's web site at www.eurand.com and will be available via replay.

About Eurand

Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary pharmaceutical technologies. Eurand has had six products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. The Company's technology platforms include bioavailability enhancement of poorly soluble drugs, custom release profiles, taste-masking orally disintegrating tablet (ODT) formulations, and drug conjugation.

Eurand is a global company with facilities in the U.S. and Europe. For more information, visit www.eurand.com.

Contact Information